Clinical Trial Update: Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating autologous cardiopoietic cell therapy for ischemic heart failure has completed, reporting on safety and efficacy outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemic Heart Failure

Drugs mentioned

• Autologous cardiopoietic cell therapy (cardiopoietic cells)

Snippet

Sponsor: Celyad Oncology SA | Conditions: Heart Failure | Phase 3 | Status: COMPLETED